Learn about Elaprase

About ELAPRASE (idursulfase)

ELAPRASE is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older.

In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with ELAPRASE has reduced spleen volume similarly to that of adults and children 5 years of age and older.

The safety and efficacy of ELAPRASE have not been established in pediatric patients less than 16 months of age.


How Does

ELAPRASE is designed to replace I2S, the enzyme that is deficient or absent in people with Hunter syndrome.


Questions About

Contact OnePath® for personalized support, insurance help, co-pay assistance, education and more.


Important Forms
& Resources

Access our directory of helpful ELAPRASE resources for patients and families.